Dr. Julie R. Bartholomew
Dr. Julie R. Bartholomew founded IMX Cosmetics, imxcosmetics.com, in Detroit in 2000. An accomplished social entrepreneur, award-winning inventor, panelist, keynote speaker and medical doctor; Dr. Bartholomew has been a named inventor on over 111 patent filings resulting in over 75 granted patents worldwide. She is one of an elite group of women representative of only 7.7% of female inventors in the United States. In 2001, Dr. Bartholomew pioneered and successfully executed the first beauty artificial intelligence (AI) formulation program for the customization of nail polish at point-of-sale. She developed an AI platform to navigate the micro-personalization of beauty, health and wellness products that can be made instantly in the retail space, online and/or at home.
Dr. Bartholomew and Bruce E. Teitelbaum co-founded RPG x IMX, rpximx.com, in 2017. Under this partnership, RPG x IMX leverages its intellectual property of more than 75 granted patents along with the founders’ long-established histories as innovators in the customization of cosmetics and consumer experiences. Their unique technology solutions dramatically re-focus shopping behavior to be tailored towards entirely personalized products and customized experiences. The transformative alliance of RPG x IMX offers real-time, in-store customization never before realized, turning passive consumers into active, highly engaged buyers.
Dr Stacie Calad-Thomson
Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.
Dr Eric Paul Bennett
